Nutritionally variant streptococci: Difference between revisions
From IDWiki
No edit summary |
No edit summary |
||
| Line 14: | Line 14: | ||
== Management == |
== Management == |
||
| − | * Susceptibilities shown below are from |
+ | * Susceptibilities shown below are from several studies[[CiteRef::kanamoto2018an]][[CiteRef::patel2017an]][[CiteRef::mushtaq2016di]] |
{| class="wikitable" |
{| class="wikitable" |
||
| Line 23: | Line 23: | ||
|- |
|- |
||
|Penicillin |
|Penicillin |
||
| − | |57% |
+ | |14 to 57% |
| − | |82% |
+ | |34 to 82% |
| − | |100% |
+ | |80 to 100% |
|- |
|- |
||
|Ampicillin |
|Ampicillin |
||
| Line 43: | Line 43: | ||
|- |
|- |
||
|Ceftriaxone |
|Ceftriaxone |
||
| − | |100% |
+ | |92 to 100% |
| − | |76% |
+ | |22 to 76% |
| − | |100% |
+ | |90 to 100% |
|- |
|- |
||
|Ceftazidime |
|Ceftazidime |
||
| Line 56: | Line 56: | ||
|100% |
|100% |
||
|100% |
|100% |
||
| + | |- |
||
| + | |Meropenem |
||
| + | |72 to 81% |
||
| + | |87 to 95% |
||
| + | |91% |
||
|- |
|- |
||
|Gentamicin |
|Gentamicin |
||
| Line 66: | Line 71: | ||
|18% |
|18% |
||
|17% |
|17% |
||
| + | |- |
||
| + | |Levofloxacin |
||
| + | |100% |
||
| + | |97 to 100% |
||
| + | |92% |
||
|- |
|- |
||
|Minocycline |
|Minocycline |
||
| Line 75: | Line 85: | ||
|100% |
|100% |
||
|100% |
|100% |
||
| − | |83% |
+ | |83 to 100% |
|- |
|- |
||
|TMP-SMX |
|TMP-SMX |
||
Latest revision as of 15:28, 11 March 2022
Background
- Require pyridoxine (vitamin B6) supplementation to group
- Also called pyridoxal-dependent or stalliting streptococci
Organisms
Clinical Manifestations
- Subacute bacterial endocarditis is the most well-known disease association
Management
| Antibiotic | Abiotrophia defectiva | Granulicatella adiacens | Granulicatella elegans |
|---|---|---|---|
| Penicillin | 14 to 57% | 34 to 82% | 80 to 100% |
| Ampicillin | 86% | 100% | 100% |
| Piperacillin | 0% | 53% | 100% |
| Cefazolin | 29% | 88% | 100% |
| Ceftriaxone | 92 to 100% | 22 to 76% | 90 to 100% |
| Ceftazidime | 0% | 0% | 50% |
| Imipenem | 100% | 100% | 100% |
| Meropenem | 72 to 81% | 87 to 95% | 91% |
| Gentamicin | 0% | 0% | 0% |
| Ciprofloxacin | 100% | 18% | 17% |
| Levofloxacin | 100% | 97 to 100% | 92% |
| Minocycline | 57% | 94% | 100% |
| Vancomycin | 100% | 100% | 83 to 100% |
| TMP-SMX | 14% | 0% | 17% |
References
- ^ Taisei Kanamoto, Shigemi Terakubo, Hideki Nakashima. Antimicrobial Susceptibilities of Oral Isolates of Abiotrophia and Granulicatella According to the Consensus Guidelines for Fastidious Bacteria. Medicines. 2018;5(4):129. doi:10.3390/medicines5040129.
- ^ Kunatum Prasidthrathsint, Mark A. Fisher. Robin Patel. Antimicrobial Susceptibility Patterns among a Large, Nationwide Cohort of Abiotrophia and Granulicatella Clinical Isolates. Journal of Clinical Microbiology. 2017;55(4):1025-1031. doi:10.1128/jcm.02054-16.
- ^ Ammara Mushtaq, Kerryl E. Greenwood-Quaintance, Nicolynn C. Cole, Peggy C. Kohner, Sherry M. Ihde, Gregory J. Strand, Lance W. Harper, Abinash Virk, Robin Patel. Differential Antimicrobial Susceptibilities of Granulicatella adiacens and Abiotrophia defectiva. Antimicrobial Agents and Chemotherapy. 2016;60(8):5036-5039. doi:10.1128/aac.00485-16.
